ArticleFluids and barriers of the CNS2026
Compartmentalized VEGF receptor expression in hypothalamic tanycytes reveals a novel non-endothelial axis of VEGF signaling : Tanycytes as a novel non-endothelial target of VEGF signaling.
Article in Fluids and barriers of the CNS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hypothalamic neurovascular and extracellular matrix remodeling: Cellular niche orchestration of immune-metabolic adaptation to nutritional stress.Reviews in endocrine & metabolic disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundVascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) are critical regulators of angiogenesis and vascular homeostasis. While VEGF signaling has been extensively studied in endothelial cells, emerging evidence suggests it also plays roles in non-endothelial brain cells. However, its spatial and cell-type-specific function within the hypothalamus, and more specifically at the level of the blood/CSF barrier, remains poorly defined. In particular, little is known about VEGF receptor expression in tanycytes, a specialized glial population that lines the third ventricle and regulates body-brain communication within the median eminence (ME), a key neurovascular interface located at the tuberal region of the hypothalamus.
methodsWe used a multi-modal approach including single-cell RNA sequencing (scRNA-seq) reanalysis, RNAscope in situ hybridization, immunohistochemistry, FACS-isolated qPCR in male and female mice, and human spatial transcriptomics to map the expression of VEGFR1 (Flt1), VEGFR2 (Kdr), and VEGF ligands in hypothalamic tanycytes across gender, development, and aging.
resultsOur data reveal a striking spatial compartmentalization of VEGFR expression in tanycytes within the ME and the arcuate (ARH), ventromedial (VMH) and dorsomedial (DMH) hypothalamus. VEGFR2 is preferentially expressed in ARH-tanycytes, while VEGFR1 is confined to VMH/DMH-tanycytes; and none of these receptors are expressed in ME-tanycytes. This pattern is unique to the ME and not observed in other circumventricular organs. VEGFR1 expression is established neonatally in mice (P0) and remains stable throughout life, whereas VEGFR2 expression becomes progressively refined postnatally, localizing to ARH-tanycytes in adulthood and showing a significant decline with aging. VEGFA is broadly expressed in all hypothalamic tanycytes, including ME-tanycytes, supporting a paracrine model of signaling. Importantly, despite species-specific differences in the spatial organization of VEGF receptors in tanycytes, the presence of VEGF ligands (Vegfa and Vegfb) and receptors in tanycytes of both mice and humans supports partial evolutionary conservation of VEGF signaling at the brain-blood interface.
conclusionOur findings unveil, for the first time a non-endothelial VEGF signaling system in hypothalamic tanycytes that is spatially compartmentalized, developmentally programmed and age-dependent. These insights reveal new roles for VEGF signaling in neurovascular and neuroendocrine function, raising important considerations for central effects of VEGF-targeted therapies in aging and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.